세계 디지털 병리학 시장 규모는 2023년 10억 달러에서 2031년 25억 7,000만 달러에 달할 것으로 예상되며, 예측 기간인 2024년부터 2031년까지 연평균 12.50% 성장할 것으로 예상됩니다. 이 시장은 의료 IT 및 생명공학 산업의 중요한 부분이며, 의료 시장에서 가장 빠른 성장률을 보이고 있습니다. 디지털 병리학 기술 채택 증가, AI와 머신러닝의 통합, 만성 질환의 유병률 증가 등의 요인이 시장을 주도하고 있습니다.
디지털 병리학은 디지털 표본 슬라이드에서 수집한 데이터를 관리하는 것을 다룹니다. 디지털 병리학은 컴퓨터 기반 기술을 이용한 가상 현미경을 사용합니다. 유리로 만든 디지털 슬라이드를 컴퓨터 화면에서 관리, 공유, 검사 및 분석할 수 있습니다. 현대 병리학은 새로운 접근 방식이 필요하며, 디지털 병리학은 분석 개선, 오류 감소, 더 나은 디스플레이, 원활한 워크플로우, 시간 단축 등 다양한 이점을 제공합니다. 의료 분야에서의 머신러닝과 AI의 발전으로 디지털 병리학의 영역이 확대되고 있으며, 홀 슬라이드 이미징(WSI)을 이용한 진단 의료에의 적용이 인정받고 있습니다. 이러한 응용의 목표는 정확하고 저렴한 비용으로 질병 진단, 예후 및 예측을 실현하는 것입니다.
AGFA Healthcare N.V.와 Corista LLC는 2024년 7월 북미에서 병리학의 디지털 전환을 위한 통합 솔루션을 출시할 예정이라고 발표했습니다. 이 첨단 기술은 병리과가 아날로그 환경에서 디지털 환경으로 전환할 때 발생하는 어려움을 극복하는 데 도움이 될 것입니다. AGFA의 엔터프라이즈 이미징 플랫폼은 여러 서비스 라인에 걸쳐 안전하고 사용자 정의 가능한 이미지 통합 접근 방식을 도입할 수 있도록 지원하며, 복잡성 감소, 임상 협력 강화, 업무 효율성 향상 등의 과제를 해결할 수 있습니다.
만성 질환의 증가는 시장 수요를 가속
당뇨병과 심장병과 같은 장기적인 건강 문제의 증가는 병원과 입원 병동에 큰 부담을 안겨주고 있습니다. 영국 심장 재단의 보고서에 따르면 관상동맥 질환(CAD)을 앓고있는 약 2억 명이 관상동맥 질환(CAD)을 앓고 있으며, 전 세계 관상동맥 질환 환자 중 57.89%가 남성, 42.8%가 여성으로 구성되어 있습니다. 전체 관상동맥질환 환자 중 남성이 57.89%, 여성이 42.11%를 차지하며, 국제당뇨병연맹(IDF)에 따르면 전 세계 5억 3,700만 명 이상의 성인이 당뇨병을 앓고 있습니다.
AI와 머신러닝의 통합, 디지털 병리학 시장을 진화시킬 것
더 많은 검사실이 인공신경망을 사용하여 분석을 강화하는 가운데, 기술의 발전으로 디지털 병리학 검사가 점점 더 널리 보급되고 있습니다. 홀 슬라이드 이미지(WSI)는 디지털 병리학의 응용 분야에서 두드러진 예입니다. 현미경 슬라이드는 WSI에 의해 디지털로 스캔되어 컴퓨터에 로드됩니다. 그런 다음 사용자는 AI 기반 분석을 위해 이미지 개선 및 디지털 변환 기술을 사용할 수 있습니다. 의료진에게 효과적인 암 치료법을 개발하는 것은 항상 문제였습니다. 전통적인 생검 결과는 매우 정확하지만 데이터를 처리하고 해석하는 데 오랜 시간이 걸리며, AI 시스템은 필요한 데이터를 신속하게 수집하고 분석하여 정확한 암 진단을 내리고 결과를 도출할 수 있습니다. 의료 네트워크와 협력하여 디지털 병리학 진단을 위한 홀 슬라이드 AI 모델을 출시할 것이라고 발표했습니다. 연구팀은 실제 환경에서 수행된 전체 슬라이드 조직 분석에서 가장 큰 규모의 AI 훈련 프로젝트 중 하나를 기반으로 한 기계 학습 모델을 발표했습니다.
이 보고서는 세계 디지털 병리학 시장에 대해 조사 분석했으며, 시장 규모와 예측, 지역별 시장 전망, 시장 역학, 경쟁 상황 등을 조사 분석했습니다.
Global digital pathology market is projected to witness a CAGR of 12.50% during the forecast period 2024-2031, growing from USD 1.00 billion in 2023 to USD 2.57 billion in 2031. The global digital pathology market is an important part of the healthcare IT and biotechnology industry, accounting for one of the fastest growth rates in the healthcare market. Factors are driving the market such as increasing adoption of digital pathology technologies, integration of AI and machine learning, and growing prevalence of chronic diseases.
Digital pathology deals with the management of data gathered from digital specimen slides. Virtual microscopy is used in digital pathology, using computer-based technologies. Digital slides made from glass can be managed, shared, examined, and analyzed on a computer screen. Modern pathologies need new approaches as digital pathology offers numerous benefits such as improved analysis, reduced errors, better views, smooth workflow, and reduced turnaround times. Due to the advancements in machine learning and artificial intelligence in healthcare, the field of digital pathology is expanding and recognizing applications in diagnostic medicine using whole-slide imaging (WSI). The goal of these applications is to achieve accurate and affordable disease diagnosis, prognosis, and prediction.
AGFA Healthcare N.V. and Corista LLC announced the launch of their integrated solution for digital transformation in pathology in North America in July 2024. This advanced technology helps pathology departments overcome the difficulties that occur in moving from an analog to a digital environment. These difficulties involve reducing complexity, enhancing clinical cooperation, and facilitating operational efficiency. The recognized enterprise imaging platform from AGFA makes it possible to implement a safe, customizable picture consolidation approach across several service lines.
Increasing Prevalence of Chronic Diseases to Accelerate the Market Demand
The rise in long-term health problems, such as diabetes and heart issues, puts a lot of pressure on hospitals and their inpatient units. The burden makes people want mobile health (mHealth) options that can help them handle ongoing health conditions better. mHealth technologies such as phone apps and medical devices let patients keep an eye on their health from home, take care of themselves, and talk to their doctors on a regular basis. As per a report from British Heart Foundation, around 200 million people have coronary artery disease (CAD), men and women constituting 57.89% and 42.11%, respectively of the global coronary artery disease patients globally. As per IDF (International Diabetes Federation), more than 537 million adults are living with diabetes globally.
Integration of Artificial Intelligence and Machine Learning to Evolve Digital Pathology Market
Digital pathology has become increasingly popular as a result of technology advancements, as more laboratories use artificial neural networks to enhance their analysis. Whole slide images (WSI) are a prominent example of applications in digital pathology. The microscope slide is digitally scanned by WSI and loaded into a computer. After that, users can use picture improvement and digital transformation methods for AI-based analysis. It has always been a problem for medical professionals to develop effective cancer treatments. The findings of a traditional biopsy are quite accurate, but processing and interpreting the data takes a long time. Artificial intelligence systems can quickly collect and analyze the necessary data, provide accurate cancer diagnoses, and produce results. In May 2024, Microsoft announced its collaboration with the University of Washington and Providence health network with the aim of launching whole-slide AI model for digital pathology. The researchers presented a machine learning model based on one of the most extensive AI training projects in whole-slide tissue analysis conducted in real-world settings.
Device Segment Dominates the Global Digital Pathology Market
The device segment had a dominant share of the global digital pathology market. It is expected to maintain at a lucrative pace throughout the forecast period. The scanner and slide management system are part of the device segment. The growing use of digital pathology for higher-resolution imaging in academic research projects is one of the major reasons behind the segment's growth. The VENTANA DP 600 slide scanner, a next-generation high-capacity device by F. Hoffmann-La Roche Ltd. that produces high-resolution digital pictures of stained tissue samples, assists in cancer diagnosis and treatment planning after the CE mark approval in June 2022.
North America Dominates the Global Digital Pathology Market
In 2023, North America held a dominant position in the global digital pathology market. This was attributed to several factors, including the development of technologically advanced pathologies due to government initiatives, ongoing deployment of R&D investments, presence of healthcare regulatory bodies, rising adoption of digital imaging, and the presence of key market players in the region who were focused on improving living and health conditions of individuals with chronic diseases. To participate in the Early Access Program, PathAI released AISight, a digital pathology platform, in March 2023 in top health systems of 13 nations, reference laboratories, medical facilities, and independent pathology organizations. Additionally, the market is growing due to the growing use of digital pathology in academic research and illness diagnostics. In June 2024, Roche announced that its whole-slide imaging system, the Roche Digital Pathology Dx, received FDA 510(k) approval. The technology analyzes and interprets digital images of scanned pathology slides to facilitate pathologists' diagnostic process. Roche is dedicated to make routine medical diagnosis possible with its digital pathology solutions, and the approval was the first step in that direction.
Future Market Scenario (2024-2031F)
A completely digital workflow from electronic microscopes to cloud-based storage and analysis is expected to accelerate digital pathology market in the forecast period. This will make remote collaboration possible and turn diagnosis faster and more effective.
Artificial intelligence and deep learning technologies will automate tasks, such as pattern recognition and computer-aided diagnosis, in digital pathology market.
More advanced applications, such as forecasting genetic alterations and treatment response based on anatomical characteristics of tissue samples, will be possible through the integration of digital pathology with AI and machine learning.
Digital pathology will enable pathologists to access and interpret slides remotely, which is crucial when there is a projected shortage of pathologists in the future.
Key Players Landscape and Outlook
Several biotechnology companies and IT companies are growing in the digital pathology market by planning and adopting new strategies. They are complying with new strategic initiatives for digital pathology technologies to increase their market presence. New agreements, contracts, acquisitions mergers, investments, and partnerships are major ways through which the market players are trying to achieve a higher market share.
Philips and Amazon Web Services announced their partnership in March 2024 to scale its cloud storage for digital pathology solutions. By enabling more pathology laboratories to use digital processes to boost productivity, Philips and AWS will progress digital pathology and assist pathology labs in effectively managing, storing, and analyzing increasing amounts of digital pathology data.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.